blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2212350

EP2212350 - Treating chronic viral infection by targetting TIM-3 [Right-click to bookmark this link]
Former [2010/31]THERAPEUTIC AND DIAGNOSTIC METHODS USING TIM-3
[2013/07]
StatusNo opposition filed within time limit
Status updated on  04.07.2014
Database last updated on 03.06.2024
Most recent event   Tooltip04.09.2015Lapse of the patent in a contracting state
New state(s): MT		published on 07.10.2015  [2015/41]
Applicant(s)For all designated states
Governing Council of the University of Toronto
Banting Institute
100 College St., Suite 413
Toronto, ON M5G 1L5 / CA
For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
[N/P]
Former [2013/49]For all designated states
Governing Council of the University of Toronto
Banting Institute
100 College St., Suite 413
Toronto, ON M5G 1L5 / CA
For all designated states
The Regents of the University of California
1111 Franklin Street, Twelfth Floor
Oakland, CA 94607-5200 / US
Former [2013/16]For all designated states
Governing Council of the University of Toronto
MaRS Center, Heritage Building 101 Collage Street, Suite 320
Ontario M5G 1L7 / CA
For all designated states
The Regents of the University of California
Office of Technology Management
University of California San Francisco
185 Berry Street, Suite 4603
San Francisco, CA 94107 / US
Former [2011/12]For all designated states
Governing Council of the University of Toronto
MaRS Center, Heritage Building 101 Collage Street, Suite 320
Ontario M5G 1L7 / CA
For all designated states
The Regents Of The University Of California
185 Berry Street, Suite 4603
San Francisco, CA 94107 / US
Former [2010/31]For all designated states
The Governing Council Of The University Of Toronto
MaRS Center, Heritage Building 101 College Street, Suite 320
Toronto, Ontario M5G 1L7 / CA
For all designated states
The Regents Of The University Of California
185 Berry Street, Suite 4603
San Francisco, CA 94107 / US
Inventor(s)01 / JONES, Richard, B.
1911-235 Bloor Street East
Toronto Ontario M4W 3Y3 / CA
02 / OSTROWSKI, Mario, A.
1-41 Spruce Street
Toronto Ontario M5A 2H8 / CA
03 / NIXON, Douglas, F.
3759 16th Street B
San Francisco California 94114 / US
04 / NDHLOVU, Lishomwa, C.
202 Kirkham Street
San Francisco, CA 94122 / US
05 / RINI, James, M.
46 Santa Barbara Road
North York Ontario M2N 2C2 / CA
 [2010/39]
Former [2010/31]01 / JONES, Richard, B.
1911-235 Bloor Street East
Toronto Ontario M4W 3Y3 / CA
02 / OSTROWSKI, Mario, A.
1-41 Spruce Street
Toronto Ontario M5A 2H8 / CA
03 / NIXON, Douglas, F.
3759 16th Street B
San Francisco California 94114 / US
04 / NDHLOVU, Lishomwa, C.
202 Kirkham Street
San Francisco California 94122 / US
05 / RINI, James, M.
46 Santa Barbara Street
North York Ontario M2N 2C2 / CA
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2013/37]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham
NG1 5GG / GB
Former [2013/35]Wright, Andrew John
Potter Clarkson LLP The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2010/31]Wright, Andrew John
Potter Clarkson LLP Park View House 58 The Ropewalk
Nottingham NG1 5DD / GB
Application number, filing date08842092.227.10.2008
[2010/31]
WO2008CA01873
Priority number, dateUS20070982771P26.10.2007         Original published format: US 982771 P
[2010/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009052623
Date:30.04.2009
Language:EN
[2009/18]
Type: A1 Application with search report 
No.:EP2212350
Date:04.08.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 30.04.2009 takes the place of the publication of the European patent application.
[2010/31]
Type: B1 Patent specification 
No.:EP2212350
Date:28.08.2013
Language:EN
[2013/35]
Search report(s)International search report - published on:CA30.04.2009
(Supplementary) European search report - dispatched on:EP03.12.2010
ClassificationIPC:C07K14/725, A61K38/17, A61K39/21, A61K39/395, A61K45/06, C07K14/705, G01N33/53, G01N33/567, G01N33/68, C07K16/28
[2010/31]
CPC:
G01N33/576 (EP,US); C07K14/70503 (US); A61P31/12 (EP);
A61P31/18 (EP); A61P37/04 (EP); A61P43/00 (EP);
C07K16/2803 (US); G01N33/56988 (EP,US); G01N33/6863 (US);
G01N33/6866 (US); C07K16/1009 (US); C12N2740/16011 (US);
C12N2770/24211 (US); G01N2333/525 (US); G01N2333/57 (US);
G01N2800/52 (EP,US); G01N2800/56 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/31]
TitleGerman:Behandlung chronischer viraler Infektionen mit TIM-3 als therapeutischen Zielmolekül[2013/07]
English:Treating chronic viral infection by targetting TIM-3[2013/07]
French:Traitement d'une infection virale chronique ciblant TIM-3[2013/07]
Former [2010/31]THERAPEUTISCHE UND DIAGNOSTISCHE VERFAHREN UNTER ANWENDUNG VON TIM-3
Former [2010/31]THERAPEUTIC AND DIAGNOSTIC METHODS USING TIM-3
Former [2010/31]MÉTHODES THÉRAPEUTIQUES ET DIAGNOSTIQUES UTILISANT LE TIM-3
Entry into regional phase25.05.2010National basic fee paid 
25.05.2010Search fee paid 
25.05.2010Designation fee(s) paid 
25.05.2010Examination fee paid 
Examination procedure25.05.2010Examination requested  [2010/31]
14.06.2011Amendment by applicant (claims and/or description)
29.08.2011Despatch of a communication from the examining division (Time limit: M06)
23.02.2012Reply to a communication from the examining division
19.04.2012Despatch of a communication from the examining division (Time limit: M04)
02.07.2012Reply to a communication from the examining division
20.03.2013Communication of intention to grant the patent
19.07.2013Fee for grant paid
19.07.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.08.2011
Opposition(s)30.05.2014No opposition filed within time limit [2014/32]
Fees paidRenewal fee
28.10.2010Renewal fee patent year 03
28.10.2011Renewal fee patent year 04
30.10.2012Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.10.2008
AT28.08.2013
BE28.08.2013
BG28.08.2013
CY28.08.2013
CZ28.08.2013
DK28.08.2013
EE28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
MC28.08.2013
MT28.08.2013
NL28.08.2013
PL28.08.2013
RO28.08.2013
SE28.08.2013
SI28.08.2013
SK28.08.2013
TR28.08.2013
IE27.10.2013
LU27.10.2013
CH31.10.2013
LI31.10.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
[2015/41]
Former [2015/34]HU27.10.2008
AT28.08.2013
BE28.08.2013
BG28.08.2013
CY28.08.2013
CZ28.08.2013
DK28.08.2013
EE28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
MC28.08.2013
NL28.08.2013
PL28.08.2013
RO28.08.2013
SE28.08.2013
SI28.08.2013
SK28.08.2013
TR28.08.2013
IE27.10.2013
LU27.10.2013
CH31.10.2013
LI31.10.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2015/32]AT28.08.2013
BE28.08.2013
CY28.08.2013
CZ28.08.2013
DK28.08.2013
EE28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
MC28.08.2013
NL28.08.2013
PL28.08.2013
RO28.08.2013
SE28.08.2013
SI28.08.2013
SK28.08.2013
TR28.08.2013
IE27.10.2013
CH31.10.2013
LI31.10.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/48]AT28.08.2013
BE28.08.2013
CY28.08.2013
CZ28.08.2013
DK28.08.2013
EE28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
MC28.08.2013
NL28.08.2013
PL28.08.2013
RO28.08.2013
SE28.08.2013
SI28.08.2013
SK28.08.2013
IE27.10.2013
CH31.10.2013
LI31.10.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/34]AT28.08.2013
BE28.08.2013
CY28.08.2013
CZ28.08.2013
DK28.08.2013
EE28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
MC28.08.2013
NL28.08.2013
PL28.08.2013
RO28.08.2013
SE28.08.2013
SI28.08.2013
SK28.08.2013
CH31.10.2013
LI31.10.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/25]AT28.08.2013
BE28.08.2013
CY28.08.2013
CZ28.08.2013
DK28.08.2013
EE28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
MC28.08.2013
NL28.08.2013
PL28.08.2013
RO28.08.2013
SE28.08.2013
SI28.08.2013
SK28.08.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/23]AT28.08.2013
BE28.08.2013
CY28.08.2013
CZ28.08.2013
DK28.08.2013
EE28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
NL28.08.2013
PL28.08.2013
RO28.08.2013
SE28.08.2013
SI28.08.2013
SK28.08.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/22]AT28.08.2013
BE28.08.2013
CY28.08.2013
DK28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
NL28.08.2013
PL28.08.2013
RO28.08.2013
SE28.08.2013
SI28.08.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/21]AT28.08.2013
BE28.08.2013
CY28.08.2013
DK28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
PL28.08.2013
SE28.08.2013
SI28.08.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/18]AT28.08.2013
BE28.08.2013
CY28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
PL28.08.2013
SE28.08.2013
SI28.08.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/14]AT28.08.2013
BE28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
PL28.08.2013
SE28.08.2013
SI28.08.2013
CY04.09.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/12]AT28.08.2013
ES28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
LV28.08.2013
PL28.08.2013
SE28.08.2013
SI28.08.2013
CY04.09.2013
NO28.11.2013
GR29.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/11]AT28.08.2013
FI28.08.2013
HR28.08.2013
LT28.08.2013
PL28.08.2013
SE28.08.2013
CY04.09.2013
NO28.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/10]AT28.08.2013
HR28.08.2013
LT28.08.2013
SE28.08.2013
CY04.09.2013
NO28.11.2013
IS28.12.2013
PT30.12.2013
Former [2014/09]AT28.08.2013
HR28.08.2013
LT28.08.2013
SE28.08.2013
NO28.11.2013
PT30.12.2013
Former [2014/08]LT28.08.2013
NO28.11.2013
PT30.12.2013
Former [2014/07]NO28.11.2013
Documents cited:Search[X]WO2005097211  (TELOS PHARMACEUTICALS INC [US], et al) [X] 10 * pp.12-23 *;
 [T]  - JONES R BRAD ET AL, "Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.", THE JOURNAL OF EXPERIMENTAL MEDICINE 24 NOV 2008 LNKD- PUBMED:19001139, (20081124), vol. 205, no. 12, ISSN 1540-9538, pages 2763 - 2779, XP002606206 [T] * the whole document *

DOI:   http://dx.doi.org/10.1084/jem.20081398
 [T]  - DAVID A HAFL ER AND VIJAY KUCHROO, "TIMs: central regulators of immune responses", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, (20081117), vol. 205, no. 12, doi:10.1084/JEM.20082429, ISSN 0022-1007, pages 2699 - 2701, XP007915343 [T] * the whole document *

DOI:   http://dx.doi.org/10.1084/jem.20082429
 [X]  - SYLVIA FRISANCHO-KISS ET AL, "Cutting Edge: T Cell Ig Mucin-3 Reduces Inflammatory Heart Disease by Increasing CTLA-4 during Innate Immunity", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20060101), vol. 176, ISSN 0022-1767, pages 6411 - 6415, XP007915344 [X] 7,9 * abstract; p.6413 *
 [XP]  - NDHLOVU L ET AL, "Tim-3 Expression Defines a Novel Population of T Cells with Highly Elevated Frequencies in Progressive HIV-1 Infection", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, (20081001), vol. 24, no. Suppl.1, ISSN 0889-2229, page 123, XP009139892 [XP] 1-11 * the whole document *
International search[X]WO2005027854  (UNIV LELAND STANFORD JUNIOR [US], et al);
 [X]WO2005033144  (BRIGHAM & WOMENS HOSPITAL [US], et al);
 [X]  - KEARLEY J. ET AL., "Th-2 driven, allergen-induced airway inflammation is reduced after treatment with anti-Tim-3 antibody in vivo.", THE J. EXPERIMENTAL MEDICINE, (2007), vol. 204, no. 6, pages 1289 - 1294, XP008133823

DOI:   http://dx.doi.org/10.1084/jem.20062093
 [Y]  - SUI L. ET AL., "Human membrane protein Tim-3 facilitates hepatitis A virus entry into target cells.", INTERNATIONAL J. OF MOLECULAR MEDICINE., (2006), vol. 17, pages 1093 - 1099, XP009102244
 [X]  - FUKUSHIMA A. ET AL., "Antibodies to T-cell and mucin domain-containing proteins (Tim)-1 and -3 suppress the induction and progression of murine allergic conjunctivitis.", BBRC., (2006), vol. 353, pages 211 - 216, XP005732939

DOI:   http://dx.doi.org/10.1016/j.bbrc.2006.12.023
 [X]  - GENG H ET AL., "Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response.", THE JOURNAL OF IMMUNOLOGY, (2006), vol. 176, no. 3, pages 1411 - 1420, XP008133825
 [YP]  - HAFLER DA ET AL., "TIMs: central regulators of immune responses.", AIDS VACCINE 2008, (20081013), XP007915343

DOI:   http://dx.doi.org/10.1084/jem.20082429
 [XP]  - ADDO M. ET AL., "Up-regulation of Tim-3 expression on T cells from HIV-1 infected individuals.", XVII International AIDS Conference, (20080803), XP008133826
ExaminationWO03063792
    - MEYERS ET AL, "The TIM gene family regulates autoimmune and allergic diseases", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, GB, (20050801), vol. 11, no. 8, ISSN 1471-4914, pages 362 - 369, XP005004055
    - EJRNAES ET AL, "Cure of chronic viral infection by neutralizing antibody treatment", AUTOIMMUNITY REVIEWS, ELSEVIER, AMSTERDAM, NL, (20070401), vol. 6, no. 5, doi:10.1016/J.AUTREV.2006.09.002, ISSN 1568-9972, pages 267 - 271, XP022015526

DOI:   http://dx.doi.org/10.1016/j.autrev.2006.09.002
    - BARBER DANIEL L ET AL, "Restoring function in exhausted CD8 T cells during chronic viral infection", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, (20060209), vol. 439, no. 7077, doi:10.1038/NATURE04444, ISSN 0028-0836, pages 682 - 687, XP002419629

DOI:   http://dx.doi.org/10.1038/nature04444
    - E John Wherry, "T cell exhaustion", Nature Immunology, (20110601), vol. 131, no. 6, doi:10.1038/ni.2035, ISSN 1529-2908, pages 492 - 499, XP055050042

DOI:   http://dx.doi.org/10.1038/ni.2035
    - L. Golden-Mason ET AL, "Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C Virus-Specific CD8+ T Cells Associated with Reversible Immune Dysfunction", Journal of Virology, (20070613), vol. 81, no. 17, doi:10.1128/JVI.00409-07, ISSN 0022-538X, pages 9249 - 9258, XP055050043

DOI:   http://dx.doi.org/10.1128/JVI.00409-07
    - C Graziosi ET AL, "Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals", Science, (19940708), vol. 265, no. 5169, doi:10.1126/science.8023143, ISSN 0036-8075, pages 248 - 252, XP055050046

DOI:   http://dx.doi.org/10.1126/science.8023143
    - "Immunomodulator therapy: Monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY,, vol. 125, no. 2, ISSN 0091-6749, (20100201), page S372, (20100210), XP026988588
    - Nobuhiro Nakamoto ET AL, "Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade", PLoS Pathogens, (20090201), vol. 5, no. 2, doi:10.1371/journal.ppat.1000313, ISSN 1553-7366, pages e1000313 - e1000313, XP055050049

DOI:   http://dx.doi.org/10.1371/journal.ppat.1000313
    - Daniel E Kaufmann ET AL, "Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction", Nature Immunology, (20070930), vol. 8, no. 11, doi:10.1038/ni1515, ISSN 1529-2908, pages 1246 - 1254, XP055050050

DOI:   http://dx.doi.org/10.1038/ni1515
    - V. Velu ET AL, "Elevated Expression Levels of Inhibitory Receptor Programmed Death 1 on Simian Immunodeficiency Virus-Specific CD8 T Cells during Chronic Infection but Not after Vaccination", Journal of Virology, (20070321), vol. 81, no. 11, doi:10.1128/JVI.00024-07, ISSN 0022-538X, pages 5819 - 5828, XP055050051

DOI:   http://dx.doi.org/10.1128/JVI.00024-07
    - DAY C L ET AL, "PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, (20060921), vol. 443, no. 7109, doi:10.1038/NATURE05115, ISSN 0028-0836, pages 350 - 354, XP002487713

DOI:   http://dx.doi.org/10.1038/nature05115
by applicantWO9502415
 US5283185
 WO9614831
 WO8809336
    - X. JIN ET AL., J EXP MED, (19990315), vol. 189, page 991
    - P. MOTTA ET AL., MEDICINA (B AIRES, (2002), vol. 62, page 245
    - O. O. YANG ET AL., J VIROL, (199704), vol. 71, page 3120
    - J. E. SCHMITZ ET AL., SCIENCE, (19990205), vol. 283, page 857
    - C. PETROVAS ET AL., J EXP MED, (20061002), vol. 203, page 2281
    - C. L. DAY ET AL., NATURE, (20060921), vol. 443, page 350
    - L. TRAUTMANN ET AL., NAT MED, (200610), vol. 12, page 1198
    - V. APPAY ET AL., J EXP MED, (20000703), vol. 192, page 63
    - M. A. OSTROWSKI ET AL., J IMMUNOL, (20001201), vol. 165, page 6133
    - M. T. ROOS ET AL., J INFECT DIS, (200008), vol. 182, page 451
    - L. E. GAMADIA; J. TEN BERGE; L. J. PICKER; R. A. VAN LIER, NAT IMMUNOL, (200203), vol. 3, page 203
    - M. J. DEETHS; R. M. KEDL; M. F. MESCHER, J IMMUNOL, (19990701), vol. 163, page 102
    - E. L. THAM; P. SHRIKANT; M. F. MESCHER, J IMMUNOL, (20020201), vol. 168, page 1190
    - D. SCOTT-ALGARA ET AL., J CLIN IMMUNOL, (200501), vol. 25, page 57
    - A. R. THOMSEN; O. MARKER, SCAND J IMMUNOL, (198608), vol. 24, page 137
    - P. SHANKAR ET AL., BLOOD, (20001101), vol. 96, page 3094
    - L. A. TRIMBLE; J. LIEBERMAN, BLOOD, (19980115), vol. 91, page 585
    - S. KOSTENSE ET AL., EUR J IMMUNOL, (200103), vol. 31, page 677
    - L. MONNEY ET AL., NATURE, (20020131), vol. 415, page 536
    - C. ZHU ET AL., NAT IMMUNOL, (200512), vol. 6, page 1245
    - H. G. ZHU; Z. H. FENG; H. GENG; G. M. ZHANG, XI BAO YU FEN ZI MIAN YI XUE ZA ZHI, (200507), vol. 21, page 403
    - A. SANCHEZ-FUEYO ET AL., NAT IMMUNOL, (200311), vol. 4, page 1093
    - C. A. SABATOS ET AL., NAT IMMUNOL, (200311), vol. 4, page 1102
    - J. V. GIORGI ET AL., J ACQUIR IMMUNE DEFIC SYNDR, (199308), vol. 6, page 904
    - E. CAO ET AL., IMMUNITY, (200703), vol. 26, page 311
    - B. EMU ET AL., J VIROL, (200511), vol. 79, page 14169
    - V. APPAY ET AL., NAT MED, (200204), vol. 8, page 379
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.